强力多巴胺激动剂培高利特在帕金森病中的应用。

The use of pergolide, a potent dopamine agonist, in Parkinson's disease.

作者信息

Lieberman A N, Goldstein M, Neophytides A, Leibowitz M, Gopinathan G, Walker R, Pact V

出版信息

Clin Pharmacol Ther. 1982 Jul;32(1):70-5. doi: 10.1038/clpt.1982.128.

DOI:10.1038/clpt.1982.128

Abstract

Pergolide, a semisynthetic ergoline and a potent long-acting adenylcyclase-linked dopamine agonist, was given to 40 patients with advanced Parkinson's disease whose response to levodopa had diminished considerably. The group included 31 patients with marked diurnal oscillations in performance ("wearing off" and/or "on-off" phenomena). Pergolide alone (7 patients) or combined with levodopa (33 patients), resulted in a reduction in disability (P less than or equal to 0.01) as assessed in both the patients' "on" and "off" periods. Pergolide also resulted in an increase (P less than or equal to 0.001) in the number of hours in which patients were on from 3.8 (+/-0.4) to 11.9 (+/-0.9). The mean daily dose of pergolide was 2.4 mg (range 0.1 to 10.0). The mean duration of the study was 12 mo (range 1 to 24). Pergolide is effective in Parkinson's disease and will change the management of patients whose response to levodopa has diminished.

摘要

培高利特是一种半合成麦角林，也是一种强效长效的与腺苷酸环化酶相关的多巴胺激动剂，被给予40例晚期帕金森病患者，这些患者对左旋多巴的反应已显著减弱。该组包括31例在功能上有明显昼夜波动（“失效”和/或“开-关”现象）的患者。单独使用培高利特（7例患者）或与左旋多巴联合使用（33例患者），在患者的“开”期和“关”期评估时均导致残疾程度降低（P≤0.01）。培高利特还使患者“开”的小时数增加（P≤0.001），从3.8（±0.4）小时增加到11.9（±0.9）小时。培高利特的平均日剂量为2.4毫克（范围0.1至10.0毫克）。研究的平均持续时间为12个月（范围1至24个月）。培高利特对帕金森病有效，并将改变对左旋多巴反应减弱的患者的治疗管理。